Item Posts Archive - Page 41 of 1770 - Medivizor
Navigation Menu

Evaluating whether administration of growth hormone improves endometrial function and reproductive outcomes in women undergoing undergoing in vitro fertilization.

Evaluating whether administration of growth hormone improves endometrial function and reproductive outcomes in women undergoing undergoing in vitro fertilization.

Posted by on Dec 4, 2022 in Infertility | 0 comments

In a nutshell This study evaluated whether the administration of growth hormone (GH) improves endometrial function and reproductive outcomes in women undergoing in vitro fertilization (IVF) cycles. The data showed that GH administration significantly improved endometrial function and increased the live birth and clinical pregnancy rate in these...

Read More

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Posted by on Dec 4, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these...

Read More

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Posted by on Dec 4, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of different programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy with cemiplimab (Libtayo)...

Read More

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Ibrutinib and venetoclax treatment for patients with relapsed or refractory chronic lymphocytic leukemia according to minimal residual disease status.

Posted by on Dec 4, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of time-limited treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that time-limited treatment with ibrutinib plus venetoclax...

Read More

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Evaluating the long-term effectiveness of fixed-duration treatment with venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Posted by on Nov 22, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness of fixed-duration treatment with venetoclax (Venclexta) plus rituximab (Rituxan) in patients with relapsed or refractory (r/r) chronic lymphocytic leukemia (CLL). The data showed that fixed-duration treatment with venetoclax plus rituximab was effective over the long term in these...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor